Drug intelligence / Profile preview

PM-4321

Development stage: Preclinical
Lead developer: Flagship Pioneering
Modality: Small Molecules
Administration: Oral

Overview

PM-4321 is an orally available small-molecule antagonist of the aryl hydrocarbon receptor (AHR) being developed as an antineoplastic agent. By inhibiting AHR signaling, PM-4321 is designed to counteract tumor-promoting and immune-suppressive pathways driven by endogenous and tumor-derived AHR ligands, thereby enhancing antitumor immunity and directly impairing cancer cell survival. Preclinical studies have shown dose-dependent tumor growth inhibition in syngeneic colorectal cancer models, supporting its potential as a targeted immunomodulatory therapy in oncology.[1][16]

Targets

AHR (Aryl hydrocarbon receptor)

Beyond the preview

Go deeper on PM-4321.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PM-4321.

Explore the full profile